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Background: In hepatocellular carcinoma (HCC), different signaling pathways are de-regulated, and among them,
the expression of the epidermal growth factor receptor (EGFR). Tyrphostin AG-1478 is a lipophilic low molecular
weight inhibitor of EGFR, preferentially acting on liver tumor cells. In order to overcome its poor drug solubility and
thus improving its anticancer activity, it was entrapped into nanostructured lipid carriers (NLC) by using safe ingredients
for parenteral delivery.
Results: Nanostructured lipid carriers (NLC) carrying tyrphostin AG-1478 were prepared by using the nanoprecipitation
method and different matrix compositions. The best system in terms of mean size, PDI, zeta potential, drug loading and
release profile was chosen to evaluate the anti-proliferative effect of drug-loaded NLC versus free drug on human
hepatocellular carcinoma HA22T/VGH cells.
Conclusions: Thanks to the entrapment into NLC systems, tyrphostin AG-1478 shows an enhanced in vitro anti-tumor
activity compared to free drug. These finding raises hope of future drug delivery strategy of tyrphostin AG-1478 -loaded
NLC targeted to the liver for the HCC treatment.
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Hepatocellular carcinoma (HCC) represents the fifth most
common cancer worldwide and third leading cause of
cancer-related mortality globally, maintaining a dismal
prognosis since intermediate and advanced stages still
account for a large percentage of cases [1]. Therapeutic op-
tions in advanced stage have been quite limited so far, until
the discovery of new therapeutic agents that target the mo-
lecular pathways involved in hepatocarcinogenesis [1].
Epidermal growth factor receptor (EGFR) is expressed
at high levels in a variety of solid tumors. In HCC, the
overexpression of this receptor has been associated with
late-stage disease, increased cell proliferation, and degree* Correspondence: marialuisa.bondi@ismn.cnr.it
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unless otherwise stated.of tumor differentiation [2-4]. In addition, activation of
EGFR pathway is a prognostic predictor of survival in
patients with HCC [5]. Therefore, EGFR represents a
good potential molecular target for biologic therapy of
HCC.
Tyrphostins are protein tyrosine kinase inhibitors.
Among them, the tyrphostin AG-1478, 4-(3-chloroani-
lino)-6,7-dimethoxyquinazoline, a competitive inhibitor
of the ATP binding site in the kinase domain of EGFR,
inhibits proliferation and induces death of liver tumor
cells through EGF receptor-dependent and independent
mechanisms [6,7]. Previous studies also revealed that tyr-
phostin AG-1478 has no cytotoxic effects per se against
normal hepatocytes, while it prevents proliferation and in-
duces apoptosis in human HCC cells [6]. Moreover, it en-
hances the sensitivity to cytotoxic drugs like cisplatin and
doxorubicin. Therefore, tyrphostin AG-1478 could be atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ever, it has not been proposed as a potential antineoplastic
drug in HCC yet.
Recently we have successfully realized novel lipid-
based drug delivery systems for several lipophilic anti-
cancer compounds by selecting the proper lipid mixture
to obtain nanostructured lipid carriers (NLC) and by
using the nanoprecipitation method [8-11]. By in vitro
studies, we have also demonstrated the increased antitu-
mor efficacy of the drug when loaded into NLC com-
pared with free drug.
Thus, in the present study, we describe the prepar-
ation of novel tyrphostin AG-1478 -loaded NLC by
selecting the suitable matrix composition in order to
achieve the chemical-physical characteristics and release
profile suitable for parenteral administration of this drug.
Moreover, on the best formulation, in vitro cell viability
assays were carried out to compare the anti-proliferative
activity of the drug entrapped into NLC versus free drug
on HA22T/VGH cells.
Results and discussion
In this paper, we describe the preparation of empty and
tyrphostin AG-1478 -loaded Nanostructured Lipid Carriers
(NLC) and their characterization from the chemical-
physical, technological and biological point of view in
order to realize a drug delivery system with suitable char-
acteristics for the treatment by parenteral administration.
Tyrphostin AG-1478, a potent and specific inhibitor of
EGFR tyrosine kinase, plays a key role in the control of
normal cellular growth and abnormal cell proliferation
[12]. This molecule is promising for the therapeutic
treatment of highly malignant forms of tumors, but it is
poorly soluble in aqueous media. Thus, the formulation
of this molecule into colloidal nanoparticulate systems,
such as NLC, could give many advantages being these
particles already proposed for drug administration in
cancer therapy [8,10].
In order to obtain a suitable carrier for tyrphostin AG-
1478, four NLC formulations were successfully prepared
by using the precipitation technique. In particular, a
solid un-pegylated lipid (Compritol 888 ATO) or a solid
pegylated lipid (Compritol HD5 ATO) were used to obtain
the lipid nanoparticles, respectively named NLC-A or
NLC-B; while a mixture between a solid lipid (Tripalmitin)
with either un-pegylated (Captex 355EP/NF) or pegylated
(Acconon CC-6) liquid lipid were used to obtain the lipid
nanoparticles, respectively named NLC-C or NLC-D. The
choice of different mixtures of solid and/or liquid lipids is
based on the consideration that the use of a liquid lipid to
prepare NLC systems could give a higher drug loading cap-
acity and a longer term stability during storage than that
obtained by using only solid lipids; while the use of a pegy-
lated lipid could give a surface modification of the obtainednanostructures which could improve their pharmacoki-
netic behaviour by increasing the mean residence time in
the bloodstream [11].
In detail, in order to obtain drug-loaded NLC, each
chosen lipid or lipid mixture was melted and tyrphostin
AG-1478 was added; then to this solution a warm etha-
nolic solution of Epikuron 200 was added. Preliminary
studies were performed in order to ensure the drug sta-
bility above the lipid melting points for a time period re-
quired to obtain the nanoparticles. No degradation process
occurs on the drug at tested conditions (data not shown).
To obtain empty NLC samples, the step involving the
addition of the drug to the melted lipid was avoided.
Empty or drug-loaded NLC were produced by disper-
sing the obtained warm organic solution, containing or
not the drug, in a cold aqueous solution containing
taurocholate sodium salt under mechanical stirring, to
allow the lipid solidification.
Finally, each colloidal aqueous NLC dispersion was
purified by exhaustive dialysis and freeze-dried. NLC sam-
ples were stored at 4 ± 1°C for successive characterization.
Since some physical-chemical and technological prop-
erties such as size, surface charge, polydispersity index
(PDI) and loading capacity (LC%) are quite critical for
biopharmaceutical behavior of NLC, all the obtained
empty and drug-loaded samples, after preparation and
purification, were characterized in terms of mean par-
ticle size and PDI in different aqueous media (bidistilled
water, NaCl 0.9 wt% and PBS aqueous saline solutions).
Obtained data are reported in Table 1.
Data indicate that the average diameter of either empty
or drug-loaded NLC samples were in the order of nano-
meter scale in all aqueous media, ranging between 60 and
250 nm.
However, PDI values are too high for NLC-A and
NLC-B samples, obtained by using only a solid lipid, es-
pecially in isotonic saline solutions. Otherwise, for those
systems obtained by using a mixture between solid and
liquid lipids, that is NLC-C and NLC-D samples, PDI
values are acceptable in all investigated media.
The results indicate that these systems could be
injected intravenously, being the mean size values suit-
able to minimize the uptake from macrophages of Mono-
nuclear Phagocyte System (MPS) [13]. In this way, these
particles could circulate in the bloodstream and poten-
tially accumulate in tumor masses as a consequence of
the well-known Enhanced Permeability and Retention
(EPR) effect [14,15]. In fact, a critical advantage in treat-
ing tumors with nanoparticulate systems comes from the
unique patho-physiological characteristics of solid tu-
mors: extensive angiogenesis and hence hypervasculari-
zation, coupled with poor lymphatic drainage, which
allow a facilitate extravasation into the tumor and EPR
effect of colloidal systems [14,15].
Table 1 Mean size, PDI in different aqueous media, Loading Capacity (LC%) and Entrapment Efficiency (EE%) values of
empty and tyrphostin AG-1478 -loaded NLC
Sample H2O NaCl 0.9 wt% PBS pH 7.4
Size (nm) PDI Size (nm) PDI Size (nm) PDI LC (wt%) EE (wt%)
Empty NLC-A 139.7 0.38 146.2 0.43 122.2 0.59 —— ——
Drug-loaded NLC-A 176.2 0.41 207.2 0.90 145.6 0.79 2.8 28.0
Empty NLC-B 62.6 0.46 120.3 0.75 106.6 0.76 —— ———
Drug-loaded NLC-B 80.1 0.49 108.4 0.49 180.1 0.58 1.7 17.0
Empty NLC-C 175.9 0.34 129.2 0.33 117.1 0.41 —— ——
Drug-loaded NLC-C 209.7 0.46 203.7 0.22 248.1 0.29 24.0 70.0
Empty NLC-D 185.5 0.29 125.6 0.28 143.8 0.25 —— ——
Drug-loaded NLC-D 189.3 0.42 248.1 0.65 181.5 0.52 24.0 70.0
Table 2 Zeta potential values in different aqueous media
of empty and tyrphostin AG-1478 -loaded NLC
ζ-potential (mV) ± S.D.
Sample In H2O In NaCl 0.9 wt% In PBS
pH 7.4
Empty NLC-A −20.1 ± 5.5 −12.3 ± 4.5 −19.6 ± 3.3
Drug-loaded NLC-A −30.3 ± 7.7 −13.6 ± 3.7 −20.4 ± 7.7
Empty NLC-B −18.7 ± 4.6 −10.4 ± 3.6 −15.4 ± 4.2
Drug-loaded NLC-B −28.5 ± 10.3 −13.2 ± 2.3 −15.1 ± 6.3
Empty NLC-C −35.7 ± 5.2 −15.9 ± 4.2 −19.7 ± 5.1
Drug-loaded NLC-C −46.9 ± 8.4 −13.1 ± 2.9 −19.6 ± 5.4
Empty NLC-D −36.7 ± 5.9 −09.4 ± 2.5 −16.6 ± 3.9
Drug-loaded NLC-D −38.4 ± 6.5 −11.4 ± 3.5 −16.6 ± 3.7
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between entrapped tyrphostin AG-1478 and the total
dried sample weight) and the EE% (expressed as weight
percent ratio between entrapped tyrphostin AG-1478
and total amount of tyrphostin AG-1478 used to prepare
the nanoparticles) of drug-loaded NLC are also reported.
Also in this case, the best values in terms of LC and EE,
evaluated by HPLC analysis on each drug-loaded system
(as reported in the Materials and Methods section), were
obtained when a mixture of solid and liquid lipids was
used as matrix composition. In fact, when tripalmitin
mixed with either un-pegylated or pegylated liquid lipid
are used as matrix composition (named respectively
NLC-C and NLC-D samples), a LC of about 24 wt% was
obtained (with a EE of 70 wt%); while when un-pegylated
or pegylated solid lipid is used as lipid matrix compos-
ition (named respectively NLC-A and NLC-B samples), a
LC of 1.7 and 2.8 were obtained (with a EE of 17 and
28 wt%, respectively).
These results can be explained considering an in-
creasing effect of the liquid lipid on the drug solubil-
ity into the lipid matrix, as other authors have already
reported [11].
The zeta potential values were also determined on the
obtained samples, and reported in Table 2.
These values resulted to be high and negative espe-
cially in bidistilled water and decreased in isotonic media
such as NaCl 0.9 wt% and PBS aqueous solutions prob-
ably for the charge shielding effect of solution ions.
However, these values assured a potential stability of
all the aqueous NLC dispersions. Moreover, a slight
increase of NLC surface charge in the presence of tyr-
phostin AG-1478 compared to empty systems was evi-
denced, and this result could be explained considering
the drug localization probably also onto the nanoparti-
cle surface.
In order to evaluate the storage stability of the ob-
tained systems, each sample (empty or drug-loaded) was
lyophilised and stored at 0°C for 3 months in the dark;after this time, mean size, PDI, zeta potential values and
LC were evaluated in bidistilled water. Obtained data,
reported in Table 3, showed that all empty and tyrphos-
tin AG-1478 -loaded NLC were stable during storage in
the tested conditions, being comparable to those of fresh
samples.
Thanks to all their chemical–physical properties and
their stability after storage, these systems could be pro-
posed for the administration by all the routes, also
intravenously.
All together these results in terms of LC, mean size
and zeta potential values indicated that the best NLC to
be proposed as drug delivery systems for tyrphostin AG-
1478 seem to be those obtained by using the mixture be-
tween tripalmitin and the liquid lipid (pegylated or not),
that is NLC-D and NLC-C. For this reason, these latter
systems were chosen to perform successive charac-
terization in terms of drug release studies and in vitro
biological assay. In particular, release studies were carried
out in different incubating media such as phosphate buf-
fer solution (PBS) at pH 7.4/ethanol mixture (80:20 v/v)
or human plasma. The use of this modified dissol-
ution medium (containing ethanol) to test preparation
Table 3 Mean size, PDI and zeta potential in bidistilled water of lyophilised empty and tyrphostin AG-1478 -loaded
NLC after storage at 0°C for 3 months in the dark

















Empty NLC-A 139.7 134.9 0.38 0.39 −20.1 ± 5.5 −19.1 ± 4.5 —— ——
Drug-loaded NLC-A 176.2 179.5 0.41 0.44 −30.3 ± 7.7 −29.4 ± 7.9 2.8 2.6
Empty NLC-B 62.6 64.4 0.46 0.49 −18.7 ± 4.6 −19.5 ± 4.9 —— ——
Drug-loaded NLC-B 80.1 84.4 0.49 0.50 −28.5 ± 10.3 −29.9 ± 16.2 1.7 1.5
Empty NLC-C 175.9 175.9 0.34 0.34 −35.7 ± 5.2 −35.7 ± 5.2 —— ——
Drug-loaded NLC-C 209.7 220.5 0.46 0.48 −46.9 ± 8.4 −42.7 ± 7.3 24.0 21.4
Empty NLC-D 185.5 192.5 0.29 0.32 −36.7 ± 5.9 −32.7 ± 4.4 —— ——
Drug-loaded NLC-D 189.3 199.3 0.42 0.48 −38.4 ± 6.5 −36.3 ± 4.4 24.0 21.8
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was in accordance to the European Pharmacopoea [16].
In Figures 1 and 2, the released drug, expressed as
weight percent ratio between released drug and the
total entrapped drug, is reported as a function of
incubation time respectively in PBS/ethanol and in
human plasma.
The release trend could be explained considering the
high hydrophobic behaviour of the drug that shows a
higher affinity for the system obtained by using the un-
pegylated liquid lipid mixed with tripalmitin as for lipid
matrix composition than for that obtained by using the
pegylated lipid. On the other hand, the lower affinity for
the pegylated lipid could give a preferential drug depos-
ition in the outsides shell of the NLC during the prepar-
ation process, and consequently a burst effect in the
release profile of the drug could be evidenced.Figure 1 Release profiles of tyrphostin AG-1478 from NLC-C and NLC-
expressed as percentage wt% of released drug as a function of incubaTherefore, a modified release of tyrphostin AG-1478
from the un-pegylated systems (NLC-C sample) can
be seen in the graphic, being the amount of released
tyrphostin AG-1478 about the 90 wt% of the total
entrapped amount after 72 hrs incubation.
It was also evaluated that the amount of un-released
tyrphostin AG-1478 was still inside NLC sample in the
intact form at every incubation time (data not shown).
This result supports the great potential of these nano-
structures as drug delivery systems for systemic adminis-
tration of drugs with low solubility and/or instability in
aqueous media.
The release profile of tyrphostin AG-1478 was also in-
vestigated in human plasma, and obtained data are re-
ported in Figure 2.
Compared to the drug release profiles obtained in PBS
at pH 7.4, a faster drug release is evidenced from eitherD samples in PBS pH 7.4/ethanol mixture (80:20 v/v) at 37 ± 0.1°C,
tion time. Each value is the mean of three experiments.
Figure 2 Drug release profiles of tyrphostin AG-1478 from from NLC-C and NLC-D samples in human plasma at 37 ± 0.1°C, expressed
as percentage wt% of released drug as a function of incubation time. Each value is the mean of three experiments.
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plasma, probably due to the different composition of the
medium, such as the presence of proteins and enzymes
in the medium. However, also in this case, the un-
pegylated system released the drug slower than the pegy-
lated one. This fact also in this case could be explained
considering a higher affinity of the drug for the system
obtained by using the un-pegylated liquid lipid mixed
with tripalmitin (sample NLC-C).
Showing the NLC-C system the best surface charge and
dimensional characteristics useful for parenteral adminis-
tration and considering their capability to give a controlled
release of tyrphostin AG-1478, a further in vitro biological
characterization was carried out on this system.
In particular, the levels of EGFR protein expressed by
the human hepatocellular carcinoma (HCC) cell line
HA22T/VGH were evaluated by Western blot analysis.
As shown in Figure 3A, the cell line intensely expressed
the receptor.
Based on this result, HA22T/VGH cells were used
for testing the inhibitory effects of tyrphostin AG-1478
free and loaded into the NLC on cell growth. In this
regard, the clonogenic assay is currently considered
the “gold standard” assay for the assessment of the
ability of drugs in killing tumor cells in vitro experi-
ments. In fact, this assay is a reliable method to meas-
ure the reproductive survival of tumor cells capable of
clonal expansion.
In this regard, to evaluate the effect of tyrphostin
AG-1478 free and loaded into NLC on the ability to
form colonies, HA22T/VGH cells were subjected to clono-
genic assay. As shown in Figure 3B, the ability of HA22T/
VGH cells to form colonies was slightly inhibited aftertreatment with free-tyrphostin AG-1478 up to a con-
centration of 25 μM, whereas, the delivery of tyrphostin
AG-1478 from the NLC inhibited colonies formation to
approximately 90% at 25 μM, therefore potentiating
the activity of tyrphostin AG-1478 to inhibit HCC cell
growth.
The results show that tyrphostin AG-1478 -loaded
NLC maintain antitumor activity, demonstrating that the
entrapment of tyrphostin AG-1478 into NLC does not
cause an activity reduction of the drug, but even reduces
cell colony survival much more than free drug.
Therefore, the results demonstrate an improved thera-
peutic efficacy of tyrphostin AG-1478 -loaded NLC com-
pared to the free drug and suggest that lipid nanoparticles
could have a great potential as tyrphostin AG-1478 tar-
geted delivery systems.
Finally, considering that solid tumors present much
more favorable conditions for preferential accumulation of
colloidal sized drug delivery systems such as NLC, these
systems can be useful for application in cancer therapy.
Conclusion
In this paper, the realization of NLC with suitable char-
acteristics for parenteral delivery of tyrphostin AG-1478
in the treatment of cancer was described. In particular,
by using the precipitation technique, different lipid com-
positions were used to obtain the best NLC system in
terms of drug loading, mean particle size, and zeta po-
tential values. The amount of tyrphostin AG-1478 en-
trapped into NLC resulted to be higher into those
systems obtained by using a mixture of solid and liquid
lipids compared to those obtained by using only the
solid lipid. Moreover, the un-pegylated nanoparticles
0.025%          0.05%          0.1%
DMSO
6.25             12.5               25
Tyrphostin (AG-1478)
6.25             12.5              25
NLC-Tyrphostin (AG-1478)



































Figure 3 A) Expression of EGFR in human hepatocellular carcinoma HA22T/VGH cells. B) Effects of free tyrphostin AG-1478,
empty-NLC and tyrphostin AG-1478-loaded NLC on the ability of human hepatocellular carcinoma cell line HA22T/VGH to form
colony. Cells were plated overnight and exposed to the indicated concentration of solvent (DMSO), free tyrphostin, empty-NLC and
tyrphostin-loaded NLC for 24 hours followed by growth in fresh culture media for 8 days, as described in Materials and Methods. Surviving
colonies were stained (upper panel) and counted (lower panel). Data are expressed as a percentage of colony in untreated cells and are
the mean ± SD of two determinations.
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lated systems and the amount of unreleased drug was still
inside of each nanoparticulate sample. This result sup-
ports the great potential of these nanostructures as drug
delivery systems with a dispersing and protecting action
on drugs, in aqueous media.Finally, in vitro biological characterization was carried
out and the HA22T/VGH cells were used for testing
the inhibitory effects of tyrphostin AG-1478 free and
loaded into the NLC on cell growth. The results show
that after treatment with free-tyrphostin AG-1478 up to
a concentration of 25 μM the ability of HA22T/VGH cells
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ery of tyrphostin AG-1478 from the NLC inhibited col-
onies formation to approximately 90% at 25 μM, therefore
potentiating the activity of tyrphostin AG-1478 to inhibit
HCC cell growth. In conclusion, tyrphostin AG-1478 -
loaded NLC maintain antitumor activity, demonstrating
that drug activity is not reduced in the presence of the
nanoparticle carrier. Moreover, the results demonstrate an
improved therapeutic efficacy of tyrphostin AG-1478 -
loaded NLC compared to the free drug and suggest that
solid lipid nanoparticles could have a great potential as tyr-




Tyrphostin AG-1478 was purchased from LC Labora-
tories (PKC Pharmaceuticals, Inc. USA). Tripalmitin
(glyceryl tripalmitate) and acetonitrile for HPLC were
purchased from Fluka (Milan, Italy). Compritol 888 ATO
(mixture of approximately mono-, di- and tri-glycerides
of behenic acid at 15, 35 and 50 wt%) and Compritol
HD5 ATO (behenoyl polyoxyl-8 glycerides) were gift
samples from Gattefossè (France). Captex 355 EP/NF
(glyceryl tricaprylate/caprate medium chain triglycerides)
and Acconon CC-6 (polyoxyethylene caprylic/capric
glycerides) were gift samples from Abitec Corporation
(Janesville, USA).
Epikuron 200 (soybean lecithin) was gift sample from
Lucas Meyer Company (Germany). Sodium tauro-
cholate was a gift from Prodotti Chimici e Alimentari
S.P.A., Basaluzzo (Alessandria, Italy). Water of double
distilled quality was obtained from MilliQ Plus sys-
tems (Millipore, Germany). The other chemicals, of
analytical grade, were obtained from Sigma Aldrich
(Milan, Italy).
HPLC (UFLC-Prominence system, Shimadzu Instrument,
Kyoto, Japan) was equipped with two pumps LC-20 AD, an
UV-visible detector SPD-20 AV, an autosample SIL-20A
HT and a column Gemini® C18 Phenomenex (250 mm,
5 μm particle size, 110 Å pores size).
Preparation of empty and drug-loaded nanostructured
lipid carriers (NLC)
Un-pegylated and pegylated NLC, empty or drug-loaded,
were prepared by the precipitation method, with appro-
priate modifications as described previously [9-11]. In
particular, a solid lipid (Compritol 888 ATO, 230 mg) or
a pegylated lipid (Compritol HD5 ATO, 230 mg) were
used to obtain the lipid matrices, respectively named
NLC-A or NLC-B; while a mixture between a solid lipid
(Tripalmitin, 180 mg) with either un-pegylated (Captex
355EP/NF, 54 mg) or pegylated (Acconon CC-6, 54 mg)
liquid lipid were used to obtain the lipid matrices,respectively named NLC-C or NLC-D. As far as of drug-
loaded samples preparation is concerned, tyrphostin
AG-1478, under mechanical stirring, was added to the
melted lipid phase. Preliminary studies were performed,
in order to ensure the drug stability above the lipid
melting point for a time period required to obtain the
nanoparticles. No degradation process occurs on the
drug at tested conditions (data not showed). After, an
ethanolic solution of Epikuron 200 (48.4 mg/ml) was added
and the organic outcome was dispersed into bidistilled
water (100 ml) containing sodium taurocholate (177.4 mg)
at 2-3°C and stirred by using an Ultraturrax T125 (IKA
Labortechnik, Staufen, Germany) at 13,500 rpm for
10 minutes. Finally, the colloidal aqueous dispersion
of NLC was purified by exhaustive dialysis in a dialysis tube
with 12,000/14,000 Dalton cut-off (Spectra/Por®, California,
USA), freeze-dried by a lyophilizer (FreeZone® Freeze Dry
System, Labconco Corporation, Missouri, USA) and stored
at 4 ± 1°C for successive characterization. Ethanol was
completely removed from the aqueous dispersions during
dialysis process.
Particle size determination
The mean diameter and width of distribution (polydisper-
sity index, PDI) of the obtained empty and drug-loaded
nanoparticles in aqueous suspension, were determined by
Photon Correlation Spectroscopy (PCS) using a Zetasizer
Nano ZS (Malvern Instrument, Herrenberg, Germany),
which utilizes Non-Invasive Back-Scattering (NIBS) tech-
nique. Each sample was appropriately diluted with fil-
tered (0.2 μm) water, NaCl 0.9 wt% and PBS at pH 7.4,
and the reading was carried out at 25° ± 1°C and at a
173° angle in respect to the incident beam. When the
measurement was carried out in NaCl 0.9 wt%, the in-
strument setting conditions were: μ = 0.902, RI =1.331;
in PBS at pH 7.4, the setting conditions were: μ = 0.980,
RI =1.334. In all cases, the temperature of measure-
ments was 25°C ± 1°C. Each suspension was kept in a
cuvette and analyzed in triplicate. The deconvolution of
the measured correlation curve to an intensity size dis-
tribution was accomplished by using a non negative least
squares algorithm.
Zeta potential measurements
The zeta potential values were measured by using princi-
ples of laser Doppler velocitometry and phase analysis
light scattering (M3-PALS technique).
For this purpose, a Zetasizer Nano ZS Malvern Instru-
ment equipped with a He-Ne laser at a power P = 4.0 mW
and with λ = 633 nm was used. Each sample was dispersed
in filtered (0.2 μm) bidistilled water, NaCl 0.9 wt% and in
PBS at pH 7.4. Instrument setting conditions were equal to
those described above for size measurements. Each sample
was analyzed in triplicate.
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An adequate HPLC method was developed to reveal
tyrphostin AG-1478 and to study its stability in phos-
phate saline buffer (PBS) at pH 7.4, as well as Loading
Capacity (LC%) and drug release profiles from drug-
loaded systems. The HPLC analysis was performed at
room temperature using the instrument described above.
A C18 column Gemini (Phenomenex, Hundsfield, UK)
packed with 5 μm particles, with dimensions 250 ×
4.60 mm i.d., was used for analysis. A mixture of aceto-
nitrile and water (30:70 v/v) containing trifluoroacetic
acid (0.1% v/v) with a flow rate of 0.1 ml/min was used as
mobile phase.
The peak was measured at a wavelength of 254 nm
and quantitatively determined by comparison with a
standard curve obtained by using drug solutions in a
mixture of acetonitrile:chloroform (1:1 v/v) at known
concentrations (tr = 9.50 min). The linearity of the
method was studied in the range 5–20 μg/ml.
Loading capacity (LC%) was determined by solving
each freeze dried NLC sample (5 mg) in 10 ml of an or-
ganic solution of acetonitrile:chloroform (1:1 v/v), fil-
tered with 0.45 μm PTFE filters and analyzed by the
HPLC method above described. The results are expressed
as actual loading percent (LC%, mg of drug encapsu-
lated per 100 mg of nanoparticles) and encapsulation effi-
ciency (EE%, ratio of actual to theoretical loading). In
order to ensure that the drug is not absorbed within the
PTFE filters, several tyrphostin AG-1478 organic solu-
tions at known concentrations were filtered and the
concentrations values, before and after filtration, were
evaluated by HPLC analysis. No significant differences in
drug concentrations were evidenced.
Storage stability
All lyophilised empty and tyrphostin AG-1478 -loaded
NLC were stored at 0°C for 3 months in the dark. After
this time, samples were dispersed in bidistilled water
and characterized in terms of mean size, PDI and zeta
potential. Moreover, chemical stability of tyrphostin AG-
1478 loaded into the NLC was evaluated by HPLC ana-
lysis, as reported above.
Drug release in PBS at pH 7.4/ethanol
Tyrphostin release was assayed on NLC samples at pre-
fixed time intervals. For this purpose, dispersions of each
batch containing 5 mg of each freeze-dried sample in a
mixture of 9.6 ml of PBS 0.01 M at pH 7.4 and 2.4 ml of
ethanol (80:20 v/v), were prepared and kept at 37 ± 0.1°C
under mechanical stirring in a Benchtop 80°C incubator
Orbital Shaker model 420 [16]. At scheduled time inter-
vals, solution aliquots (1 ml) were taken out from the
outside of the dialysis membrane and replaced with
fresh PBS aqueous-ethanolic solution. Release profile wasdetermined by comparing the amount of released tyr-
phostin AG-1478 as a function of incubation time with
the total amount of drug loaded into NLC. Data were
corrected taking in account the dilution procedure. A
control experiment to determine the release behavior of
the free tyrphostin AG-1478 was also performed. A sus-
pension of free tyrphostin AG-1478 in PBS aqueous-
ethanolic solution at pH 7.4 was prepared at the same
concentration of drug entrapped in the NLC, put into a
dialysis tube (MWCO 5,000 Da) and immersed into
the proper medium. The amount of tyrphostin AG-1478
was detected as reported above.
Drug release in human plasma
Tyrphostin release was assayed on NLC samples at pre-
fixed time intervals. For this purpose, dispersions of each
batch containing 2.5 mg of each freeze-dried sample
in 2 ml of human plasma were prepared and kept at
37 ± 0.1°C under mechanical stirring in a Benchtop
80°C incubator Orbital Shaker model 420. At suitable
time intervals, samples were filtered through 0.45 μm
nylon filters; then acetonitrile was added and the ob-
tained blend was centrifuged at 4°C and 12,000 rpm for
15 min. Then the supernatant was filtered by 0.45 μm
PTFE filters and analyzed by HPLC.
Western blot analysis
For Western blot analysis whole cellular lysates were ob-
tained using RIPA buffer (Cell Signaling Technologies
Inc., Beverly, MA, USA). Protein concentrations of super-
natants were determined with the Bio-Rad protein assay
kit (Bio-Rad Laboratories SrL, Milan, Italy), and Western
blotting were performed as previously described [17], with
primary antibodies raised against β-actin (Sigma-Aldrich
Srl, Milan, Italy) and EGFR (Cell Signaling Technologies
Inc., Beverly, MA, USA).
Cell culture and clonogenic assay
The human hepatocellular carcinoma HA22T/VGH cell
line, a poorly differentiated human hepatocellular carcin-
oma cell line established from a surgical specimen of
hepatocellular carcinoma obtained from a 56-year-old
Chinese male was kindly provided by Professor Massimo
Levrero (Laboratory of Gene Expression, Fondazione
Andrea Cesalpino, University of Rome “La Sapienza”,
Rome, Italy) [18]. Cells were cultured in Roswell Park
Memorial Institute (RPMI) medium (Sigma, Milan, Italy)
supplemented with 10% heat-inactivated fetal calf
serum (FCS) (Gibco, Milan, Italy), 2 mM L-glutamine,
1 mM sodium pyruvate, 100 units/ml penicillin and
100 μg/ml streptomycin (all reagents were from Sigma)
in a humidified atmosphere at 37°C in 5% CO2. Cells hav-
ing a narrow range of passage number were used for all
experiments.
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growth was assessed using a clonogenic assay. For this
analysis, 200 cells were plated onto six-well plates in
growth medium and after overnight attachment cells were
exposed to various concentrations of solvent (DMSO), free
tyrphostin AG-1478, empty NLC and NLC-loaded tyr-
phostin AG-1478 for 24 hrs. The cells were then washed
with medium and allowed to grow for 8 days under
inhibitor-free or nanoparticles-free conditions, after which
the cell colonies were fixed with 70% ethanol at 4°C for
20 min and stained with crystal violet (0.1% in H2O) for
5 min. The plates were rinsed with water, air-dried, photo-
graphed and evaluated for colony estimation. Colonies
containing more than 50 cells were counted. Relative col-
ony formation was determined by the ratio of the average
number of colonies in cells treated with free-tyrphostin
AG-1478, empty-NLC and NLC-loaded tyrphostin AG-
1478 to the average number of colonies in cells treated
with DMSO. All experiments were performed in duplicate
and repeated twice.
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